AstraZeneca Playing Leapfrog In Immunotherapy: How It Plans To Lead From Behind
Executive Summary
AstraZeneca has not been at the front of the PD-1/L1 immune checkpoint inhibitor race, but execs explain how the company is making strategic choices in immuno-oncology to make it first to the finish line in unique areas.
You may also be interested in...
AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory
While most eyes were on AstraZeneca's keenly awaited MYSTIC lung cancer study of Imfinzi, its PACIFIC trial has ducked under the radar and hit investors with the nicest kind of surprise. The results could have wider implications for IO in earlier-stage cancers.
Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline
The large-molecule specialist is delivering on the plan put in place with its 2007 acquisition, with late-stage advances in psoriasis, rheumatoid arthritis, asthma, COPD and lupus, execs say in interview with “The Pink Sheet.” Leading the way for parent company AstraZeneca in cancer immunotherapy, MedImmune says it is well positioned in that widely watched space with clinical candidates in four different mechanisms of action.